Co-administration of silymarin and deferoxamine against kidney, liver and heart iron deposition in male iron overload rat model

International Journal of Preventive Medicine

Volumn 5, Issue 1, 2014, Pages 110-116

  Navidi Shishaone, Mitra ^a,b   Mohhebi, Soheila ^a,b   Nematbakhsh, Mehdi ^a,c   Roozbehani, Shahla ^b   Talebi, Ardeshir ^a   Pezeshki, Zahra ^a   Eshraghi Jazi, Fatemeh ^a   Mazaheri, Safoora ^a   Shirdavani, Sohiela ^a   Gharagozloo, Marjan ^a   Moaeidi, Behjat Alsaadat ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c Isfahan MN Institute of Basic and Applied Sciences Research   (Iran)

Author keywords

Deferoxamine; Heart; Iron deposition; Kidney; Liver; Silymarin

Indexed keywords

BIOLOGICAL MARKER; CREATININE; DEFEROXAMINE; FERRITIN; MALONALDEHYDE; NITRITE; NITROGEN; SILYMARIN; SODIUM CHLORIDE; UREA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FERRITIN BLOOD LEVEL; HEART; HISTOPATHOLOGY; IRON OVERLOAD; IRON STORAGE; KIDNEY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY MASS; LIVER; LIVER DISEASE; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; UREA NITROGEN BLOOD LEVEL; WEIGHT GAIN;

EID: 84893154474     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005;202:199-211.
2. Prabhu VP, Prabhu RS. Iron overlod in beta thalassemia-A review. J Biosci Technol 2009;1:20-31.
3. Kondo A, Deguchi J, Okada S. Intranuclear iron deposition in hepatocytes and renal tubular cells in mice treated with ferric nitrilotriacetate. Virchows Arch 1998;433:543-8.
4. Sponsel HT, Alfrey AC, Hammond WS, Durr JA, Ray C, Anderson RJ. Effect of iron on renal tubular epithelial cells. Kidney Int 1996;50:436-44.
5. Madhusudhan KS, Oberoi R. Renal iron deposition in aplastic anemia: Magnetic resonance imaging appearance. Indian J Nephrol 2011;21:134-5.
6. Rakow-Penner R, Glader B, Yu H, Vasanawala S. Adrenal and renal corticomedullary junction iron deposition in red cell aplasia. Pediatr Radiol 2010;40:1955-7.
7. Schein A, Enriquez C, Coates TD, Wood JC. Magnetic resonance detection of kidney iron deposition in sickle cell disease: A marker of chronic hemolysis. J Magn Reson Imaging 2008;28:698-704.
8. Wang H, Nishiya K, Ito H, Hosokawa T, Hashimoto K, Moriki T. Iron deposition in renal biopsy specimens from patients with kidney diseases. Am J Kidney Dis 2001;38:1038-44.
9. Ibrahim el-SH, Rana FN, Johnson KR, White RD. Assessment of cardiac iron deposition in sickle cell disease using 3.0 Tesla cardiovascular magnetic resonance. Hemoglobin 2012;36:343-61.
10. Murphy CJ, Oudit GY. Iron-overload cardiomyopathy: Pathophysiology, diagnosis, and treatment. J Card Fail 2010;16:888-900.
11. Wang Y, Wu M, Al-Rousan R, Liu H, Fannin J, Paturi S, et al. Iron-induced cardiac damage: Role of apoptosis and deferasirox intervention. J Pharmacol Exp Ther 2011;336:56-63.
12. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood 2012;120:3657-69.
13. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-73.
14. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000;95:2776-9.
15. Franchini M, Gandini G, Veneri D, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: An update. Blood 2004;103:747-8.
16. Guo C, Wang P, Zhong ML, Wang T, Huang XS, Li JY, et al. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem Int 2013;62:165-72.
17. Najafzadeh H, Jalali MR, Morovvati H, Taravati F. Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat. J Med Toxicol 2010;6:22-6.
18. Obejero-Paz CA, Yang T, Dong WQ, Levy MN, Brittenham GM, Kuryshev YA, et al. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med 2003;141:121-30.
19. Zhang L, Hu R, Li M, Li F, Meng H, Zhu G, et al. Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury. Neurol Sci 2013;34:639-45.
20. Gupta A, Sharma S, Chopra K. Reversal of iron-induced nephrotoxicity in rats by molsidomine, a nitric oxide donor. Food Chem Toxicol 2008;46:537-43.
21. Li YH, Chien SP, Chu PY, Liu MY. Prophylactic and therapeutic effects of a subcutaneous injection of sesame oil against iron-induced acute renal injury in mice. JPEN J Parenter Enteral Nutr 2012;36:344-8.
22. Gupta A, Chopra K. Effect of tocotrienols on iron-induced renal dysfunction and oxidative stress in rats. Drug Chem Toxicol 2009;32:319-25.
23. Bostanci MO, Bas O, Bagirici F. Alpha-tocopherol decreases iron-induced hippocampal and nigral neuron loss. Cell Mol Neurobiol 2010;30:389-94.
24. Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S, et al. Silybin, a new iron-chelating agent. J Inorg Biochem 2001;85:123-9.
25. Gharagozloo M, Khoshdel Z, Amirghofran Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: A comparison with desferrioxamine. Eur J Pharmacol 2008;589:1-7.
26. Hutchinson C, Bomford A, Geissler CA. The iron-chelating potential of silybin in patients with hereditary haemochromatosis. Eur J Clin Nutr 2010;64:1239-41.
27. Gharagozloo M, Karimi M, Amirghofran Z. Immunomodulatory effects of silymarin in patients with β-thalassemia major. Int Immunopharmacol 2013;16:243-7.
28. Senturk H, Kabay S, Bayramoglu G, Ozden H, Yaylak F, Yucel M, et al. Silymarin attenuates the renal ischemia/reperfusion injury-induced morphological changes in the rat kidney. World J Urol 2008;26:401-7.
29. Turgut F, Bayrak O, Catal F, Bayrak R, Atmaca AF, Koc A, et al. Antioxidant and protective effects of silymarin on ischemia and reperfusion injury in the kidney tissues of rats. Int Urol Nephrol 2008;40:453-60.
30. Kaur G, Athar M, Alam MS. Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. Invest New Drugs 2010;28:703-13.
31. Ninsontia C, Pongjit K, Chaotham C, Chanvorachote P. Silymarin selectively protects human renal cells from cisplatin-induced cell death. Pharm Biol 2011;49:1082-90.
32. Nematbakhsh M, Pezeshki Z, Moaeidi BA, Eshraghi-Jazi F, Talebi A, Nasri H, et al. Protective role of silymarin and deferoxamine against iron dextran-induced renal iron deposition in male rats. Int J Prev Med 2013;4:286-92.
33. Kadkhodaee M, Gol A. The role of nitric oxide in iron-induced rat renal injury. Hum Exp Toxicol 2004;23:533-6.
34. Gaenzer H, Marschang P, Sturm W, Neumayr G, Vogel W, Patsch J, et al. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 2002;40:2189-94.
35. Mascitelli L, Pezzetta F. High iron stores and impaired endothelial function in prediabetic subjects. Am J Cardiol 2006;97:1550.
36. Mascitelli L, Pezzetta F, Sullivan JL. Iron chelation by green tea flavonoids and improved endothelial function in chronic smokers. Circ J 2006;70:1523.
37. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001;103:2799-804.
38. Metzger IF, Sertorio JT, Tanus-Santos JE. Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol (Oxf) 2006;188:123-7.
39. Kelm M, Preik-Steinhoff H, Preik M, Strauer BE. Serum nitrite sensitively reflects endothelial no formation in human forearm vasculature: Evidence for biochemical assessment of the endothelial L-arginine-NO pathway. Cardiovasc Res 1999;41:765-72.
40. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 2006;40:295-302.
41. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: Food sources and bioavailability. Am J Clin Nutr 2004;79:727-47.
42. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193-203.